Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Ms CD3 MOLCPX BUV737 17A2 50ug

RRID:AB_2870130
Type: Antibody

Proper Citation

BD Biosciences Cat# 612803, RRID:AB_2870130

Antibody Information

URL: http://antibodyregistry.org/AB_2870130

Proper Citation: BD Biosciences Cat# 612803, RRID:AB_2870130

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD3 MOLCPX BUV737 17A2 50ug

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: 17A2

Antibody ID: AB_2870130

Vendor: BD Biosciences

Catalog Number: 612803

Record Creation Time: 20250820T030447+0000

Record Last Update: 20250820T151733+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD3 MOLCPX BUV737 17A2 50ug.

No alerts have been found for Ms CD3 MOLCPX BUV737 17A2 50ug.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Malhotra SV, et al. (2026) YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression. Molecular cancer therapeutics.

Shamskhou EA, et al. (2026) Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes. Immunity.

Vurnek D, et al. (2026) Protocol for mapping murine myeloid bone marrow progenitors and their differentiation into CD103+ cDC1s and CD301b+ cDC2s. STAR protocols, 7(2), 104508.

Zha M, et al. (2026) Single-cell omics and flow cytometry identify distinct immune states of dural and brain-infiltrating IL-17-producing ?? T cells after experimental stroke. Journal of neuroinflammation, 23(1).

Diers AR, et al. (2025) Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy. Cancer research communications, 5(2), 327.

Amon L, et al. (2025) GM-CSF and specific type 2 cytokines induce CD103+ and CD301b+ cell states in cDC1s and cDC2s. Cell reports, 44(12), 116589.

Wang L, et al. (2025) Mucosal boosting increases protective efficacy of an influenza vaccine in mice. iScience, 28(6), 112721.

Lamorte S, et al. (2025) Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. Cancer cell, 43(5), 955.

Wallace RP, et al. (2024) Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics. Cell reports. Medicine, 5(1), 101345.

Yeh AC, et al. (2024) Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation. Immunity, 57(7), 1648.

Kumar S, et al. (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. Cell reports. Medicine, 5(9), 101698.

Istomine R, et al. (2023) The eIF4EBP-eIF4E axis regulates CD4+ T cell differentiation through modulation of T cell activation and metabolism. iScience, 26(5), 106683.

Vidal SJ, et al. (2023) Attenuated Mycobacterium tuberculosis vaccine protection in a low-dose murine challenge model. iScience, 26(6), 106963.

Chen HA, et al. (2023) Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity. Cancer discovery, 13(2), 432.

Ataide MA, et al. (2022) Lymphatic migration of unconventional T cells promotes site-specific immunity in distinct lymph nodes. Immunity, 55(10), 1813.